Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 47% Improvement Relative Risk c19early.org/s Solh et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 643 patients in the USA Lower mortality with remdesivir (p=0.001) Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 Favors remdesivir Favors control
Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint)
Solh et al., Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository, medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline; substantial unadjusted confounding by indication likely.
risk of death, 47.0% lower, HR 0.53, p < 0.001, treatment 63 of 219 (28.8%), control 202 of 424 (47.6%), NNT 5.3, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Solh et al., 20 Oct 2020, retrospective, database analysis, USA, preprint, 5 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.16.20214130; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY Ali A. El-Solh, MD, MPH ; Umberto G. Meduri, MD ; Yolanda Lawson, MS ; Michael Carter, 1-3 4 1 PharmD , Kari A. Mergenhagen, PharmD 1 1 1 VA Western New York Healthcare System, Buffalo, NY.; Division of Pulmonary, Critical Care, and 2 Sleep Medicine, Department of Medicine; Department of Epidemiology and Environmental Health, 3 State University of New York at Buffalo School of Medicine and Biomedical Sciences and School of Public Health and Health Professions; Buffalo, NY; and Memphis VA Medical Center, Memphis, 4 Tennessee Please address any correspondence and reprint request to: Ali El Solh, MD, MPH VA Western New York Healthcare System 3495 Bailey Avenue Buffalo, NY 14215 Tel (716) 862-7392 Fax (716) 862-6526 Email: solh@buffalo.edu Summary conflict of interest statements: AES has received grant support from the Department of Veterans Affairs. UGM has received grant support from the Department of Veterans Affairs. YL declares no conflict to report. MC declares no conflict to report. KM declares no conflict to report. Funding information: None Acknowledgments: The views expressed in this manuscript do not communicate an official position of the Department of Veterans Affairs. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.10.16.20214130; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . ABSTRACT Background: Mortality attributable to coronavirus disease-19 (COVID-19) 2 infection occurs mainly through the development of viral pneumonia-induced acute respiratory distress syndrome (ARDS). Research Question: The objective of the study is to delineate the clinical profile, predictors of disease progression, and 30-day mortality from ARDS using the Veterans Affairs Corporate Data Warehouse. Study Design and Methods: Analysis of a historical cohort of 7,816 hospitalized patients with confirmed COVID-19 infection between January 1, 2020, and August 1, 2020. Main outcomes were progression to ARDS and 30-day mortality from ARDS, respectively. Results: The cohort was comprised predominantly of men (94.5%) with a median age of 69 years (interquartile range [IQR] 60-74 years). 2,184 (28%) were admitted to the intensive care unit and 643 (29.4%) were diagnosed with ARDS. The median Charlson Index was 3 (IQR 1-5). Independent predictors of progression to ARDS were body mass index (BMI)≥ 40 kg/m , diabetes, lymphocyte 2 counts<700x109/L, LDH>450 U/L, ferritin >862 ng/ml, C-reactive protein >11 mg/dL, and Ddimer >1.5 ug/ml. In contrast, the use of an anticoagulant lowered the risk of developing ARDS (OR 0.66 [95% CI 0.49-0.89]. Crude 30-day mortality rate from ARDS was 41% (95% CI 38%-45%). Risk of death from ARDS was..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit